Martindale Pharma®, Burton Hospital Announces Agreement
News Jun 02, 2016
Martindale Pharma has announced that it has signed a multi-year exclusive manufacturing agreement with Burton Hospitals NHS Foundation Trust. Under the terms of the agreement, Burton Hospitals NHS Foundation Trust will supply a number of Martindale Pharma’s key specialty generic products including Bismuth Iodoform Paraffin Paste (BIPP) and Lidocaine and Phenylephrine Topical Solution, both routine treatments in Ear Nose and Throat (ENT) surgery. Financial terms were not disclosed.
Michael Clark, Chief Marketing Officer, commented: “This news follows two years of collaborative work with the Burton Hospital, one of our best performing contract manufacturing partners. We believe this new agreement demonstrates how pharmaceutical companies can support NHS manufacturing units and offer patients the best drugs currently available on the market.”
Martindale Pharma is recognised as a strategic partner to the NHS, having maintained a close partnership with NHS manufacturing units over the years, as well as supporting NHS staff with first-class training. For the past six years, Martindale Pharma has worked with the UCL School of Pharmacy and London North West Healthcare NHS Trust’s Q3P Qualified Person (QP) Training Course providing academic and practical training to NHS Qualified Person trainees: as part of the course the pharmaceutical packaging module is hosted annually at Martindale Pharma’s Romford facility.
Michael Clark added “We are very pleased to be able to share our expertise and knowledge in the manufacturing industry with trainee QPs and NHS Manufacturing units. Our expertise, combined with our modern, upgraded UK manufacturing facility not only allows us to manufacture high quality medicines efficiently, but supply these to a wide range of countries and health care systems, notably the UK where we have over 100 different products on contract to supply the UK NHS.”
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE